Sairopa

SAIROPA

Sairopa is a clinical-stage company that develops novel treatments for cancer by modulating the patient’s immune system. Cancer treatment was revolutionized by the introduction of so-called immune checkpoint inhibitors, that enhances the immune response against the patient’s own tumor. However only about 30% of cancer patients find benefit from such therapies. It is well accepted that for a productive anti-cancer immune response to happen, all elements of the cancer-immunity cycle need to be functional: tumor-antigen release, antigen-processing, -presentation, T-cell activation and blockade of local immunosuppression in the tumor.

Early 2021 Sairopa acquired, backed by Van Herk Investments, a portfolio of therapeutic antibodies from Chinook Therapeutics. These antibodies were originally developed by BioNovion/Aduro Biotech Europe using the proprietary B-Select antibody platform that was also used to identify pembrolizumab (Keytruda™), BION-1301 and MK-5890 (Guelen et al., 2022).

Mission

It is Sairopa’s mission to develop agents that can modulate this cancer-immunity cycle on different points:

ADU-1805, Sairopa’s proprietary anti-SIRPalpha antibody is enhancing tumor cell uptake and presentation to the T cells to induce priming and activation (Voets et al., 2019).

ADU-1604, Sairopa’s proprietary and unique anti-CTLA4 antibody is enhancing T cell priming and activation to raise a higher diversity of tumor cytotoxic immune cells. ADU-1604 is currently being tested in Phase 1 Clinical trials to assess for safety and efficacy in patients suffering from advanced melanoma.

Discovery Programs (undisclosed) that inhibit local immunosuppression in the tumor.

Sairopa cancer immunity cycle

Sairopa programs target distinct parts of the cancer-immunity cycle (adapted from Chen and Mellman, 2013)

About

Sairopa’s team has a leading reputation in the field of immune oncology and is laser-focused to deliver the therapeutic antibodies towards clinical benefit in cancer patients.

The company is based in Rotterdam, the Netherlands.

About Sairopa

Meet our team

Sairopa’s team has a leading reputation in the field of immune oncology and is laser-focused to deliver the therapeutic antibodies towards clinical benefit in cancer patients.

The company is based in Rotterdam, The Netherlands.

Latest news

Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPa

— IND filing for ADU-1805 expected in Q1 2023,...